Minerva Neurosciences Corp (NERV) Projected Future Earnings
The current planned profit level of Minerva Neurosciences (NERV) demonstrates recovery potential following regulatory setbacks. The foundation for growth is built upon the unique properties of roluperidone for the treatment of schizophrenia and a full production outsourcing model that minimizes costs. This chart confirms a trend reversal, while shows the current metric value, capturing market expectations for the future revenues of Minerva Neurosciences.
Minerva Neurosciences - analytical breakdowns and key metrics (NERV)
- price and consensus price forecast:
- market capitalization details:
- book capitalization indicators:
- debt and liquidity data:
Debt to Equity Minerva Neurosciences|NERV - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Minerva Neurosciences|NERV - Company Debts|Debts to Book Capitalization Minerva Neurosciences, Inc.|NERV - Company Long-Term Debts|Company Current Liabilities Minerva Neurosciences|Quick Liquidity minervaneurosciences.com
- net income and valuation ratios data:
NERV - Company Profit|Projected Future Earnings Minerva Neurosciences|NERV - Market Cap to Earnings|Projected Price to Earnings Minerva Neurosciences Inc|NERV - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Minerva Neurosciences Corp|NERV - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Minerva Neurosciences|NERV - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months minervaneurosciences.com|NERV - Expected net earnings per share growth this year|Earnings growth forecast for next year Minerva Neurosciences
- issuer revenue and sales details:
Summary company analysis:minervaneurosciences.com, NERV
This indicator measures the discounted value of expected net income, filtering out market noise to determine the asset's fundamental value. The metric assesses the company's ability to generate cash flow over the long term. For Minerva Neurosciences (NERV), the profit scale forecast depends directly on the commercial success of roluperidone within the schizophrenia therapy niche. The profit scale trend allows for the identification of the risk of overpaying for future successes. This serves as a key filter for assessing the fair value of a biotech startup.
Main competitors
BIIB (Biogen) - Projected Future Earnings|Net Profit Forecast NBIX (Neurocrine Biosciences, Inc.)|Projected Future Earnings RGC|Axsome Corp - Net Profit Forecast|Projected Future Earnings ACAD (ACADIA Corp)|XENE: Net Profit Forecast|Viking Therapeutics Inc - Projected Future Earnings|Expected Net Profit Supernus Pharmaceuticals, Inc.|Catalyst Pharmaceuticals Inc (CPRX) - Expected Profit|DNLI (Denali Therapeutics Inc) - Expected Profit|Expected Profit Harmony Biosciences Holdings, Inc.|Expected Profit BHVN|Future Profit AMLX (Amylyx Pharmaceuticals, Inc.)|Future Net Profit TRVI|Expected Profit Praxis Precision Medicines, Inc. PRAX|Anavex Corp - Expected Profit|CBLL: Future Profit|Expected Net Income PRTA (prothena.com)|Alector, Inc. (ALEC) - Expected Profit|Net Profit Forecast ANNX|Expected Profit Omeros Corp.|Neurogene Therapeutics (NGNE) - Company Profit Forecast|Projected Future Earnings ACIU|VYGR (Voyager Therapeutics) - Expected Net Income|Projected Future Earnings NMRA (neumoratx.com)|SCLX: Net Profit Forecast|TVGN - Expected Profit|Expected Net Profit Alpha Cognition Inc.|CGTX: Projected Future Earnings|inhibikase.com (IKT) - Projected Future Earnings|Expected Profit Cassava Sciences Inc|ASRT - Projected Net Profit|Expected Profit Coya (COYA)|Projected Future Earnings VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Future Profit|Company Profit Forecast Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - Projected Future Earnings|Company Profit Forecast alteritytherapeutics.com ATHE|CLNN: Projected Future Earnings|Expected Net Profit PepGen Corp (PEPG)|Expected Profit Jupiter Neurosciences, Inc.|RLMD: Expected Net Income|Projected Future Earnings ANVS|Future Profit Grace Tx GRCE|Expected Profit Firefly Neuroscience, Inc AIFF|KLTO: Net Profit Forecast|NRSN - Expected Profit|RVPH: Expected Profit|MTVA (MetaVia Inc.) - Future Profit|NeurAxis Inc. (NRXS) - Projected Future Earnings|Expected Profit Helius Medical|Passage Bio, Inc. - Forward Earnings|Future Profit NEUP (Neuphoria)|ATHA - Expected Net Profit|Projected Future Earnings ADXN (addextherapeutics.com)|Alzamend (ALZN) - Expected Net Profit|CYCN: Future Profit|Expected Net Profit Protagenic Therapeutics Inc.|pasitheaclinics.com (KTTA) - Expected Profit|Expected Net Profit Cortigent Medical (CRGT)|ATXI (Avenue Therapeutics Inc) - Projected Future Earnings|BCLI (Brainstorm Cell Therapeutics Inc.) - Future Net Profit|Projected Future Earnings CARA|CHRO - Expected Net Profit|Eliem Therapeutics - Future Profit|Intra-Cellular (ITCI) - Expected Net Profit|LBPH - Expected Profit|MRNS - Projected Future Earnings|NKGN: Projected Future Earnings|NeuroBo Pharma (NRBO) - Projected Future Earnings|Future Profit SAGE|Net Profit Forecast SNPX (Synaptogenix, Inc.)|Expected Profit Trevena, Inc (TRVN)|VIGL (Vigil Neuroscience Inc.) - Expected Net Income|Expected Profit Anew Medical WENA|Future Net Profit CERE (Cerevel)
